3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Classical hematology
1
Conditions
Anemia, Iron-Deficiency
2
Plexosarcoma
1
Lymphoproliferative Disorders
1
Gastrointestinal Stromal Tumors
1
Anemia
1
Interventions
Rituximab
4
Tacrolimus
3
fludarabine
2
cobomarsen
2
Peripheral Blood Stem Cell Transplantation
2
Ganciclovir
2
Etoposide
2
Cyclophosphamide
2
Busulfan
2
Antilymphocyte Serum
2
ruxolitinib
1
ponatinib
1
pomalidomide
1
ibritumomab tiuxetan
1
fludarabine phosphate
1
ferric carboxymaltose
1
epratuzumab
1
denileukin diftitox
1
dacetuzumab
1
beta-Glucans
1
arginine butyrate
1
Vorinostat
1
Vincristine
1
Valganciclovir
1
Stem Cell Transplantation
1
Sirolimus
1
Prednisone
1
Oxycodone
1
Mycophenolic Acid
1
Morphine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoproliferative Disorders
×
ferric carboxymaltose
×
Clear all
NCT01100879
2022-05-09
AOC-MM
Vifor Pharma
Phase 4
Terminated
3 enrolled